Óscar Cordero-Llana

Dr. Óscar Cordero-Llana

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Molecular Therapy
Verified
Journal Article
Open access
KMKirsty J. McMillan
Kirsty J. McMillan
TMTracey K. Murray
Tracey K. Murray
NBNora Bengoa-Vergniory
Nora Bengoa-Vergniory
ÓCÓscar Cordero-Llana
Óscar Cordero-Llana
JCJane Cooper
Jane Cooper
MCMaeve Caldwell
Maeve Caldwell
Abnormal alpha-synuclein (α-synuclein) expression and aggregation is a key characteristic of Parkinson's disease (PD). However, the exact mechanism(s) linking α-synuclein to the other central feature of PD, dopaminergic neuron loss, remains unclear. Therefore, improved cell and in vivo models are needed to investigate the role of α-synuclein in dopaminergic neuron loss. MicroRNA-7 (miR-7) regulates α-synuclein expression by binding to the 3' UTR of the Synuclein Alpha Non A4 Component of Amyloid Precursor (SNCA) gene and inhibiting its translation. We show that miR-7 is decreased in the substantia nigra of patients with PD and, therefore, may play an essential role in the regulation of α-synuclein expression. Furthermore, we have found that lentiviral-mediated expression of miR-7 complementary binding sites to stably induce a loss of miR-7 function results in an increase in α-synuclein expression in vitro and in vivo. We have also shown that depletion of miR-7 using a miR-decoy produces a loss of nigral dopaminergic neurons accompanied by a reduction of striatal dopamine content. These data suggest that miR-7 has an important role in the regulation of α-synuclein and dopamine physiology and may provide a new paradigm to study the pathology of PD.

2 April 2018 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
SHSimon J. Hawkins
Simon J. Hawkins
LCLucy A. Crompton
Lucy A. Crompton
ASAman Sood
Aman Sood
MSMargaret Saunders
Margaret Saunders
NBNoreen T. Boyle
Noreen T. Boyle
MCMaeve Caldwell
Maeve Caldwell

1 February 2015 in Molecular Therapy
Verified
Journal Article
Open access
ÓCÓscar Cordero-Llana
Óscar Cordero-Llana
BHBenjamin C Houghton
Benjamin C Houghton
FRFederica Rinaldi
Federica Rinaldi
HTHannah Taylor
Hannah Taylor
RYRafael J. Yáñez-Muñoz
Rafael J. Yáñez-Muñoz
MCMaeve Caldwell
Maeve Caldwell
Cerebral Dopamine Neurotrophic Factor (CDNF) and Mesencephalic Astrocyte-derived Neurotrophic factor (MANF) are members of a recently discovered family of neurotrophic factors (NTFs). Here we used intranigral or intrastriatal lentiviral vector-mediated expression to evaluate their efficacy at protecting dopaminergic function in the 6-OHDA model of Parkinson’s disease (PD). In contrast to the well-studied Glial-Derived Neurotrophic Factor (GDNF), no beneficial effects were demonstrated by striatal overexpression of either protein. Interestingly, nigral overexpression of CDNF decreased amphetamine-induced rotations and increased tyroxine hydroxylase (TH) striatal fibre density but had no effect on numbers of TH+ cells in the SN. Nigral MANF overexpression had no effect on amphetamine-induced rotations or TH striatal fibre density but resulted in a significant preservation of TH+ cells. Combined nigral overexpression of both factors led to a robust reduction in amphetamine-induced rotations, greater increase in striatal TH-fibre density and significant protection of TH+ cells in the SN. We conclude that nigral CDNF and MANF delivery is more efficacious than striatal delivery. This is also the first study to demonstrate that combined NTF can have synergistic effects that result in enhanced neuroprotection, suggesting that multiple NTF delivery may be more efficacious for the treatment of PD than the single NTF approaches attempted so far.

1 January 2014 in Neuropharmacology
Verified
Journal Article
Closed access
JBJ.L. Badger
J.L. Badger
ÓCÓscar Cordero-Llana
Óscar Cordero-Llana
EHE.M. Hartfield
E.M. Hartfield
RWR. Wade-Martins
R. Wade-Martins

7 January 2011 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
ÓCÓscar Cordero-Llana
Óscar Cordero-Llana
SSS A Scott
S A Scott
SMS L Maslen
S L Maslen
JAJ M Anderson
J M Anderson
JBJ Boyle
J Boyle
MCMaeve Caldwell
Maeve Caldwell
Neuronal differentiation from expanded human ventral mesencephalic neural precursor cells (NPCs) is very limited. Astrocytes are known to secrete neurotrophic factors, and so in order to enhance neuronal survival from NPCs, we tested the effect of regional astrocyte-conditioned medium (ACM) from the rat cortex, hippocampus and midbrain on this process. Human NPC's were expanded in FGF-2 before differentiation for 1 or 4 weeks in ACM. The results show that ACM from the hippocampus and midbrain increase the number of neurons from expanded human NPCs, an effect that was not observed with cortical ACM. In addition, both hippocampal and midbrain ACM increased the number and length of phosphorylated neurofilaments. MALDI-TOF analysis used to determine differences in media revealed that although all three regional ACMs had cystatin C, α-2 macroglobulin, extracellular matrix glycoprotein and vimentin, only hippocampal and midbrain ACM also contained clusterin, which when immunodepleted from midbrain ACM eliminated the observed effects on neuronal differentiation. Furthermore, clusterin is a highly glycosylated protein that has no effect on cell proliferation but decreases apoptotic nuclei and causes a sustained increase in phosphorylated extracellular signal-regulated kinase, implicating its role in cell survival and differentiation. These findings further reveal differential effects of regional astrocytes on NPC behavior and identify clusterin as an important mediator of NPC-derived neuronal survival and differentiation.

6 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKaren R Mifsud
Karen R Mifsud
CKClare L. M. Kennedy
Clare L. M. Kennedy
SSSilvia Salatino
Silvia Salatino
ESEshita Sharma
Eshita Sharma
EPEmily M. Price
Emily M. Price
JRJohannes M.H.M. Reul
Johannes M.H.M. Reul
Glucocorticoid hormones (GCs) — acting through hippocampal mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) — are critical to physiological regulation and behavioural adaptation. We conducted genome-wide MR and GR ChIP-seq and Ribo-Zero RNA-seq studies on rat hippocampus to elucidate MR- and GR-regulated genes under circadian variation or acute stress. In a subset of genes, these physiological conditions resulted in enhanced MR and/or GR binding to DNA sequences and associated transcriptional changes. Binding of MR at a substantial number of sites however remained unchanged. MR and GR binding occur at overlapping as well as distinct loci. Moreover, although the GC response element (GRE) was the predominant motif, the transcription factor recognition site composition within MR and GR binding peaks show marked differences. Pathway analysis uncovered that MR and GR regulate a substantial number of genes involved in synaptic/neuro-plasticity, cell morphology and development, behavior, and neuropsychiatric disorders. We find that MR, not GR, is the predominant receptor binding to >50 ciliary genes; and that MR function is linked to neuronal differentiation and ciliogenesis in human fetal neuronal progenitor cells. These results show that hippocampal MRs and GRs constitutively and dynamically regulate genomic activities underpinning neuronal plasticity and behavioral adaptation to changing environments.